Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 26, Issue 6, Pages 2037-2041Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfr174
Keywords
adefovir dipivoxil; hepatitis B virus; lamivudine-resistance; renal transplantation
Categories
Funding
- BRISTOL-MEYERS-SQUIBB
- SCHERING-PLOUGH
- ROCHE
- NOVARTIS
- GILEAD
- VERTEX
Ask authors/readers for more resources
Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV. Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay. Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy. Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available